EP355: Vitamin K and Lipid Lowering Therapy

Welcome to my podcast. I am Doctor Warrick Bishop, and I want to help you to live as well as possible for as long as possible. I’m a practising cardiologist, best-selling author, keynote speaker, and the creator of The Healthy Heart Network. I have over 20 years as a specialist cardiologist and a private practice of over 10,000 patients. Podcast Summary Introduction Dr. Ulrich Bishop hosts this episode to explore the often-overlooked relationship between vitamin K and cholesterol-lowering medications. The episode examines how fat-soluble vitamins like vitamin K play crucial roles beyond blood clotting, particularly in bone health and calcium regulation, and how common lipid-management drugs may inadvertently impact vitamin K status in the body. Key Takeaways: Vitamin K is a fat-soluble vitamin essential not only for blood clotting but also for bone health and calcium regulation through activation of the protein osteocalcin. Vitamin K activates matrix GLA protein (MGP), a potent inhibitor of soft tissue calcification, helping ensure calcium deposits in bones rather than in arteries or heart valves. Vitamin K supports bone health by promoting osteoblast (bone-building cell) differentiation, reducing osteoclast formation (bone-resorbing cells), and decreasing inflammatory processes at the bone surface. Statins, which are HMG-CoA reductase inhibitors, may reduce the body's production of menaquinone-4 (vitamin K2) by blocking the enzymatic pathway that converts acetyl-CoA to downstream molecules needed for vitamin K synthesis. Ezetimibe, commonly combined with statins for cholesterol lowering, blocks the NPC1L1 receptor in the gut that is responsible for absorbing both cholesterol and vitamin K, potentially creating a dual mechanism of vitamin K depletion. Research on warfarin (a vitamin K antagonist) shows significant negative impacts on bone mineral density, particularly in men, supporting the clinical importance of adequate vitamin K status. While solid clinical evidence linking statin and ezetimibe use to vitamin K deficiency outcomes remains limited, the mechanistic pathway is theoretically sound and warrants consideration. Dr. Bishop recommends that patients on lipid-lowering medications consider vitamin K supplementation to mitigate potential deficiency and support optimal bone health and calcium regulation.